Solid Biosciences (SLDB) News Today $3.27 +0.02 (+0.62%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Solid Biosciences: Promising Advancements and Strategic Initiatives Drive Buy RatingJanuary 17 at 8:05 PM | markets.businessinsider.comSolid Biosciences: Strategic Advancements and Promising Pipeline Justify Buy RatingJanuary 17 at 8:05 PM | markets.businessinsider.comSolid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic MedicinesJanuary 15 at 4:05 PM | globenewswire.comSolid Biosciences Inc. (NASDAQ:SLDB) CFO Sells $15,843.97 in StockJanuary 14, 2025 | insidertrades.comKevin Tan Sells 4,073 Shares of Solid Biosciences Inc. (NASDAQ:SLDB) StockSolid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) CFO Kevin Tan sold 4,073 shares of the firm's stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $3.89, for a total value of $15,843.97. Following the completion of the transaction, the chief financial officer now owns 24,789 shares in the company, valued at approximately $96,429.21. This trade represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.January 13, 2025 | marketbeat.comPromising Developments and Strategic Advancements Support Buy Rating for Solid BiosciencesJanuary 13, 2025 | markets.businessinsider.comQ1 EPS Forecast for Solid Biosciences Reduced by AnalystSolid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Research analysts at Leerink Partnrs dropped their Q1 2025 earnings per share (EPS) estimates for shares of Solid Biosciences in a report issued on Thursday, January 9th. Leerink Partnrs analyst J. Schwartz now expects that the company will earJanuary 13, 2025 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Earns "Buy" Rating from HC WainwrightJanuary 13, 2025 | americanbankingnews.comSolid Biosciences (NASDAQ:SLDB) Now Covered by Analysts at Truist FinancialJanuary 11, 2025 | americanbankingnews.comSolid Biosciences’ Innovative Gene Therapy SGT-212 Gains Buy Rating Amid Promising Preclinical Results and FDA ApprovalJanuary 11, 2025 | markets.businessinsider.comSolid Biosciences (SLDB) Receives a Buy from Piper SandlerJanuary 11, 2025 | markets.businessinsider.comSolid Biosciences (NASDAQ:SLDB) Receives Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $16.00 target price on shares of Solid Biosciences in a report on Friday.January 10, 2025 | marketbeat.comSolid Biosciences: Promising Advancements in Gene Therapy and Strategic Positioning Justify Buy RatingJanuary 9, 2025 | markets.businessinsider.comSolid Biosciences: Promising Gene Therapy Advancements and Strategic Positioning Drive Buy RatingJanuary 8, 2025 | markets.businessinsider.comSolid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | globenewswire.comSolid Bio draws buy from Truist on valuation and catalystsJanuary 8, 2025 | msn.comSolid Biosciences Outpaces Competitors In Duchenne Gene Therapy DevelopmentJanuary 8, 2025 | benzinga.comTruist Securities Initiates Coverage of Solid Biosciences (SLDB) with Buy RecommendationJanuary 8, 2025 | msn.comSolid Biosciences (NASDAQ:SLDB) Coverage Initiated by Analysts at Truist FinancialTruist Financial initiated coverage on shares of Solid Biosciences in a research report on Wednesday. They issued a "buy" rating and a $16.00 price target on the stock.January 8, 2025 | marketbeat.comSolid Biosciences Gains FDA Clearance for New Drug ApplicationJanuary 8, 2025 | marketwatch.comSolid Biosciences's IND For Gene Therapy To Treat Friedreich's Ataxia Gets FDA ClearanceJanuary 8, 2025 | markets.businessinsider.comSolid Biosciences gains 12% to $4.40 on FDA clearance of SGT-212 INDJanuary 8, 2025 | msn.comSolid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's AtaxiaJanuary 7, 2025 | globenewswire.comSolid Biosciences Inc. (NASDAQ:SLDB) Given Average Rating of "Buy" by AnalystsSolid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) has received a consensus rating of "Buy" from the twelve brokerages that are covering the company, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a buy rating and four have assigned a strong buy rating tDecember 28, 2024 | marketbeat.comSolid Biosciences Receives Buy Rating Amid Promising Developments and Accelerated Approval Prospects for SGT-003December 23, 2024 | markets.businessinsider.comSolid Biosciences Added to the Nasdaq Biotechnology IndexDecember 23, 2024 | globenewswire.comSolid Biosciences Inc SLDBDecember 22, 2024 | morningstar.comSolid Biosciences (NASDAQ:SLDB) Raised to Strong-Buy at WedbushWedbush upgraded shares of Solid Biosciences to a "strong-buy" rating in a research note on Thursday.December 14, 2024 | marketbeat.comSolid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: AnalystDecember 13, 2024 | benzinga.comWedbush Initiates Coverage of Solid Biosciences (SLDB) with Outperform RecommendationDecember 13, 2024 | msn.comWedbush Begins Coverage on Solid Biosciences (NASDAQ:SLDB)Wedbush assumed coverage on shares of Solid Biosciences in a report on Friday. They set an "outperform" rating and a $16.00 price objective for the company.December 13, 2024 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Solid Biosciences (NASDAQ:SLDB)HC Wainwright reiterated a "buy" rating and set a $16.00 price objective on shares of Solid Biosciences in a research note on Thursday.December 12, 2024 | marketbeat.comCitizens Jmp Upgrades Solid Biosciences (NASDAQ:SLDB) to "Strong-Buy"Citizens Jmp upgraded Solid Biosciences to a "strong-buy" rating in a report on Tuesday.December 11, 2024 | marketbeat.comBuy Rating Affirmed: Solid Biosciences’ Strong Potential in Gene Therapy for DMD Highlighted by Innovative Technologies and Attractive ValuationDecember 11, 2024 | markets.businessinsider.comJMP Securities Initiates Coverage of Solid Biosciences (SLDB) with Market Outperform RecommendationDecember 11, 2024 | msn.comSolid Biosciences (NASDAQ:SLDB) Now Covered by JMP SecuritiesJMP Securities began coverage on Solid Biosciences in a research report on Tuesday. They set an "outperform" rating and a $15.00 price objective for the company.December 10, 2024 | marketbeat.comPoint72 Asset Management L.P. Acquires 330,234 Shares of Solid Biosciences Inc. (NASDAQ:SLDB)Point72 Asset Management L.P. raised its holdings in Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) by 292.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 443,010 shares of the company's stock after purchasing anDecember 10, 2024 | marketbeat.comStrategic Collaboration with Mayo Clinic Boosts Solid Biosciences’ Buy Rating for Cardiac Gene Therapy AdvancementsDecember 7, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Solid Biosciences (SLDB), Foghorn Therapeutics (FHTX) and KalVista Pharmaceuticals (KALV)December 6, 2024 | markets.businessinsider.comSolid Biosciences announces collaboration with Mayo ClinicDecember 5, 2024 | markets.businessinsider.comSolid Biosciences Inc. (NASDAQ:SLDB) Insider Jessie Hanrahan Sells 4,610 SharesDecember 5, 2024 | insidertrades.comSolid Biosciences Announces Collaboration with Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene TherapiesDecember 4, 2024 | markets.businessinsider.comSolid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) have earned an average recommendation of "Buy" from the nine analysts that are covering the stock, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating on tDecember 3, 2024 | marketbeat.comVestal Point Capital LP Has $19.52 Million Stake in Solid Biosciences Inc. (NASDAQ:SLDB)Vestal Point Capital LP raised its stake in Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) by 5.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,800,000 shares of the company's stock after purchasing anNovember 29, 2024 | marketbeat.comSolid Biosciences to Participate at Upcoming Investor ConferencesNovember 26, 2024 | globenewswire.comCantor Fitzgerald Brokers Reduce Earnings Estimates for SLDBSolid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Stock analysts at Cantor Fitzgerald cut their FY2024 earnings per share estimates for Solid Biosciences in a research report issued to clients and investors on Monday, November 18th. Cantor Fitzgerald analyst C. Duncan now anticipates that theNovember 21, 2024 | marketbeat.comSolid Biosciences Reports Increased Losses Amid R&D FocusNovember 19, 2024 | markets.businessinsider.comWhat is Chardan Capital's Estimate for SLDB FY2024 Earnings?Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Research analysts at Chardan Capital reduced their FY2024 earnings per share estimates for shares of Solid Biosciences in a report released on Monday, November 11th. Chardan Capital analyst Y. Livshits now anticipates that the company will postNovember 14, 2024 | marketbeat.comSolid Biosciences to Present at the Jefferies London Healthcare ConferenceNovember 14, 2024 | globenewswire.comSolid Biosciences price target lowered to $12 from $15 at JPMorganNovember 13, 2024 | markets.businessinsider.com Get Solid Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter. Email Address SLDB Media Mentions By Week SLDB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLDB News Sentiment▼0.380.50▲Average Medical News Sentiment SLDB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLDB Articles This Week▼123▲SLDB Articles Average Week Get Solid Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Annexon News Today Keros Therapeutics News Today Mereo BioPharma Group News Today Rapport Therapeutics News Today Ginkgo Bioworks News Today Entrada Therapeutics News Today Oruka Therapeutics News Today Tourmaline Bio News Today Xeris Biopharma News Today Altimmune News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLDB) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredDonald Trump is about to free crypto from its chains …With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Solid Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Solid Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SLDB Stock Alerts